Selecting Appropriate Patients with NSCLC for Neoadjuvant Therapy

Joshua Sabari, MD, describes which stage groups of patients with NSCLC should receive neoadjuvant therapies, and which therapies are typically used.

Related Content:

The Evolving Treatment Paradigm for Stage I-IIIA NSCLCLung CancerOncLive Peer Exchange®

Zongertinib Could Alter SOC in HER2-Mutated Advanced NSCLC

Less Is More With Advanced Surgical Approaches in Early-Stage NSCLC

Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial